- AstraZeneca’s bold ambition to deliver 20 new medicines by the close of the decade
- How AstraZeneca is adopting innovative manufacturing strategies to harness the potential of advanced therapies and modalities
- Exploring the unique challenges and opportunities of new modalities while meeting the growing demand for targeted therapies
- The role of smart factories and flexible, modular and continuous manufacturing processes in accelerating and scaling supply
- AstraZeneca’s commitment to reducing its environmental impact through sustainable practices and energy-efficient operation
Sheena Behn
Vice President Vaccine & Immune Therapies Supply Chain & Vice President for Oncology Supply
AstraZeneca
Sheena Behn is an established global leader in the Pharmaceutical Industry with significant supply chain, manufacturing and development experience and expertise. She has worked at AstraZeneca for 25 years.
Sheena is currently VP Vaccine and Immune Therapies Supply Chain and VP for Oncology Supply, based in Cambridge, UK.
She was previously based in Gothenburg as VP R&D Supply Chain (2012-2014) running the global group for Clinical Supply at AZ; and before that VP for Wuxi Manufacturing site for 3 years, based in China (2010-2012).
Sheena is a Pharmacist who started her career working in London hospitals, before working in pharmaceutical development with GSK and then AZ before joining Operations in 2007.
